Type

Public

HQ

Parsippany Troy Hills, US

Founded

1987

Size (employees)

65 (est)

Website

InterpaceDiagnostics.comInterpace Diagnostics was founded in 1987 and is headquartered in Parsippany-Troy Hills, US

Interpace Diagnostics has an office in Parsippany-Troy Hills

Parsippany Troy Hills, US (HQ)

300 Interpace Pkwy

Interpace Diagnostics's revenue was reported to be $3.5 m in Q1, 2017

USD

## Revenue (Q1, 2017) | 3.5 m |

## Gross profit (Q1, 2017) | 1.7 m |

## Gross profit margin (Q1, 2017), % | 49% |

## Net income (Q1, 2017) | 2.4 m |

## EBIT (Q1, 2017) | 3.7 m |

## Market capitalization (19-Jul-2017) | 7.6 m |

## Closing share price (19-Jul-2017) | 0.9 |

## Cash (31-Mar-2017) | 7.1 m |

Interpace Diagnostics's current market capitalization is $7.6 m.

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 150.8 m | 119.9 m | 9.4 m | 13.1 m |

## Revenue growth, % | (20%) | (92%) | 39% | |

## Cost of goods sold | 126.4 m | 101.4 m | 6.9 m | 6.6 m |

## Gross profit | 24.4 m | 18.5 m | 2.5 m | 6.4 m |

## Gross profit Margin, % | 16% | 15% | 27% | 49% |

## Sales and marketing expense | 5.5 m | |||

## R&D expense | 1.6 m | |||

## General and administrative expense | 10.5 m | |||

## Operating expense total | 28.7 m | 32 m | 42.9 m | 12.9 m |

## EBIT | (4.3 m) | (13.5 m) | (40.4 m) | (6.4 m) |

## EBIT margin, % | (3%) | (11%) | (428%) | (49%) |

## Interest expense | 602 k | 3.7 m | (2.1 m) | |

## Net Income | (4.6 m) | (16.1 m) | (11.4 m) | (8.3 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 31.6 m | 29.2 m | 38.3 m | 36.3 m | 36.6 m | 3 m | 3.6 m | 3.3 m | 3.5 m |

## Cost of goods sold | 26.8 m | 25.5 m | 30.7 m | 30.2 m | 29.4 m | 1.2 m | 1.8 m | 1.8 m | 1.8 m |

## Gross profit | 4.8 m | 3.7 m | 7.6 m | 6.1 m | 7.2 m | 1.9 m | 1.8 m | 1.5 m | 1.7 m |

## Gross profit Margin, % | 15% | 13% | 20% | 17% | 20% | 61% | 49% | 44% | 49% |

## Sales and marketing expense | 1.5 m | 1.3 m | 1.3 m | 1.1 m | |||||

## R&D expense | 232 k | 414 k | 1 m | 323 k | 357 k | 659 k | 306 k | ||

## General and administrative expense | 7.2 m | 7.3 m | 6.4 m | 2.8 m | 2 m | 2.9 m | 1.5 m | ||

## Operating expense total | 7.4 m | 7.8 m | 7.4 m | 4.7 m | 3.7 m | 4.8 m | 3 m | ||

## EBIT | (2.5 m) | (4.2 m) | (2.9 m) | (5.9 m) | (4 m) | (3.8 m) | (2.9 m) | (6.5 m) | 3.7 m |

## EBIT margin, % | (8%) | (14%) | (8%) | (16%) | (11%) | (125%) | (80%) | (196%) | 107% |

## Interest expense | (848 k) | (884 k) | (969 k) | (203 k) | (858 k) | (539 k) | (254 k) | ||

## Income tax expense | 173 k | 3 k | |||||||

## Net Income | (2.7 m) | (4.3 m) | (3.9 m) | (7 m) | (4.9 m) | (4.8 m) | (2.3 m) | (7.5 m) | 2.4 m |

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 45.6 m | 23.1 m | 8.3 m | 602 k |

## Accounts Receivable | 2.4 m | 8.5 m | 2.8 m | 2.2 m |

## Current Assets | 62.7 m | 44.9 m | 19.2 m | 4.2 m |

## PP&E | 2.8 m | 3.2 m | 1.5 m | 929 k |

## Goodwill | 2.5 m | 15.5 m | ||

## Total Assets | 69.1 m | 115.9 m | 67.7 m | 41.8 m |

## Accounts Payable | 2.4 m | 4.3 m | 1.6 m | 2.3 m |

## Total Debt | 27.2 m | 8.4 m | ||

## Current Liabilities | 31.4 m | 33.6 m | 23.4 m | 16.2 m |

## Total Liabilities | 35.2 m | |||

## Additional Paid-in Capital | 130.2 m | 134.2 m | 132.5 m | 127.7 m |

## Retained Earnings | (83.8 m) | (99.9 m) | (111.3 m) | (119.6 m) |

## Total Equity | 32.5 m | 20.1 m | 13 m | 6.5 m |

## Debt to Equity Ratio | 1.3 x | 0.6 x | ||

## Debt to Assets Ratio | 0.2 x | 0.1 x | ||

## Financial Leverage | 2.1 x | 5.8 x | 5.2 x | 6.4 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 35.6 m | 27 m | 17 m | 14.4 m | 9 m | 4.3 m | 3 m | 1.7 m | 7.1 m |

## Accounts Receivable | 3.8 m | 3.4 m | 13.4 m | 11.9 m | 12.3 m | 2.8 m | 3 m | 2.8 m | 2.3 m |

## Current Assets | 53.2 m | 42.2 m | 43.1 m | 39.3 m | 32.1 m | 11.7 m | 9.6 m | 6.7 m | 10.7 m |

## PP&E | 2.8 m | 2.9 m | 3.3 m | 3.1 m | 2.8 m | 1.3 m | 1.2 m | 1.1 m | 770 k |

## Goodwill | 2.5 m | 2.5 m | 15.5 m | 15.7 m | 15.7 m | ||||

## Total Assets | 59.5 m | 62.2 m | 112.6 m | 107.6 m | 99.3 m | 56.8 m | 53.5 m | 46 m | 47 m |

## Accounts Payable | 2.1 m | 2.9 m | 3 m | 4.4 m | 4.5 m | 1.2 m | 1.3 m | 1.4 m | 2.6 m |

## Current Liabilities | 25.6 m | 28.7 m | 34 m | 34.9 m | 31.5 m | 19.7 m | 19.2 m | 19.9 m | 13 m |

## Additional Paid-in Capital | 131.6 m | 132 m | 134.6 m | 129.1 m | 129.6 m | 125.8 m | 125.8 m | 125.8 m | 143.3 m |

## Retained Earnings | (88.1 m) | (92.4 m) | (103.8 m) | (110.7 m) | (115.6 m) | (116 m) | (118.4 m) | (125.9 m) | (117.2 m) |

## Total Equity | 29.4 m | 25.4 m | 16.6 m | 10.3 m | 5.9 m | 8.3 m | 6 m | 24.6 m | |

## Financial Leverage | 2 x | 2.4 x | 6.8 x | 10.4 x | 16.9 x | 6.8 x | 8.9 x | 1.9 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | (4.6 m) | (16.1 m) | (11.4 m) | (8.3 m) |

## Depreciation and Amortization | 4.5 m | |||

## Accounts Receivable | 4.8 m | |||

## Accounts Payable | 143 k | |||

## Cash From Operating Activities | (3.5 m) | (16.4 m) | (19.8 m) | (8.9 m) |

## Purchases of PP&E | (1.8 m) | (2.9 m) | (353 k) | |

## Cash From Investing Activities | (3.3 m) | (25.4 m) | 26.4 m | |

## Cash From Financing Activities | (314 k) | 19.2 m | (21.4 m) | 1.2 m |

## Income Taxes Paid | 235 k | 115 k | 242 k | 71 k |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (2.7 m) | (4.3 m) | (3.9 m) | (7 m) | (4.9 m) | (4.8 m) | (2.3 m) | (7.5 m) | 2.4 m |

## Accounts Receivable | 3.8 m | 3.4 m | 13.4 m | 11.9 m | 12.3 m | 2.8 m | 3 m | 2.8 m | 2.3 m |

## Accounts Payable | 2.1 m | 2.9 m | 3 m | 4.4 m | 4.5 m | 1.2 m | 1.3 m | 1.4 m | 2.6 m |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 53.4 k |

## Financial Leverage | 1.9 x |

Interpace Diagnostics's Facilities was reported to be 2 in FY, 2016. Interpace Diagnostics's Patent Applications was reported to be 16 in FY, 2016

- Source: SEC Filings